Cardiff, United Kingdom

Marco Migliore



Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2012-2016

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Marco Migliore: Innovator in Anti-Viral Compounds

Introduction

Marco Migliore is a distinguished inventor based in Cardiff, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of anti-viral compounds. With a total of 3 patents to his name, Migliore's work focuses on innovative solutions for viral infections.

Latest Patents

One of Migliore's latest patents involves anti-viral pyrimidine nucleoside derivatives. This compound is designed for use in the treatment or prophylaxis of viral infections, such as chicken pox or shingles caused by the Varicella Zoster virus. The compound has a general formula where specific elements are defined, including variations of X, Y, Z, and R, which contribute to its efficacy. In preferred embodiments, the amino acid moiety may include valine, leucine, isoleucine, or alanine, particularly valine.

Career Highlights

Throughout his career, Marco Migliore has worked with notable organizations, including University College Cardiff Consultants Limited and KU Leuven Research & Development. His experience in these institutions has allowed him to collaborate on various research projects that advance the field of virology.

Collaborations

Migliore has collaborated with esteemed colleagues such as Christopher McGuigan and Jan Balzarini. These partnerships have fostered a productive environment for innovation and research in anti-viral therapies.

Conclusion

Marco Migliore's contributions to the field of anti-viral compounds highlight his role as a key innovator in medicinal chemistry. His patents and collaborations reflect a commitment to advancing healthcare solutions for viral infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…